Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04018937
Recruitment Status : Recruiting
First Posted : July 15, 2019
Last Update Posted : July 15, 2019
Sponsor:
Information provided by (Responsible Party):
John Horan, Emory University

Brief Summary:
This study aims to enroll 58 pre-adolescent (<10 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor. All participants will go through a pre-transplant evaluation to find out if there are health problems that will keep them from being able to receive the transplant. It usually takes 2 to 3 months to complete the pre-transplant evaluation and make the arrangements for the transplant. Once they are found to be eligible for transplant, participants will be admitted to the hospital and will start transplant conditioning. Conditioning is the chemotherapy and other medicines given to prepare them to receive donor cells. It prevents the immune system from rejecting donor cells. Conditioning will start 21 days before transplant. Once they complete conditioning, participants will receive the bone marrow transplant. After the transplant, participants will stay in the hospital for 4-6 weeks. After they leave the hospital, participants will be followed closely in the clinic. Outpatient treatment and frequent clinic visits usually last 6 to 12 months. Routine medical care includes at least a yearly examination for many years after transplant by doctors and nurses familiar with sickle cell disease and transplant. The researchers will collect and study information about participants for 5 years after transplant.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: Fludarabine Drug: Alemtuzumab Drug: Melphalan Phase 2

Detailed Description:

The use of HLA matched sibling donor (MSD) hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD) is evolving. Because of the low risk for graft versus host disease (GVHD) associated with younger age, HSCT is increasingly being performed prior to adolescence. The use of less gonadotoxic reduced intensity regimens (RIC) are more commonly be utilized to lessen the risk for infertility. Finally, with the recognition that most children, even those with relatively mild courses, will develop debilitating morbidities as adults and ultimately suffer an early death, HSCT is being offered to children across a wider spectrum of SCD severity. Long reserved for severely affected children, HSCT is being performed for a growing number of less severely affected children.

This trial is designed to prospectively assess HSCT under these conditions. Eligibility will be limited to children less than 10 years of age who have an HLA MSD who is also less than 10 years. A RIC regimen - fludarabine, alemtuzumab and melphalan (FAM) - will be employed. Finally, SCD severity criteria will be broadened to include less several affected children as well as those who are severely affected.

This study has the following two specific aims:

Specific Aim #1: To prospectively assess the safety and efficacy of HSCT using FAM conditioning in children with SCD of varying severity who are under 10 years of age.

Specific Aim #2: To address current gaps in our understanding of the long-term effects of HSCT in children with SCD, by longitudinally assessing sickle cell related cerebrovascular disease, sickle cell related nephropathy and health related quality of life.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial
Actual Study Start Date : March 22, 2019
Estimated Primary Completion Date : January 2027
Estimated Study Completion Date : January 2027


Arm Intervention/treatment
Experimental: Reduced Intensity Conditioning with FAM
Children with SCD will received reduced intensity conditioning with fludarabine, alemtuzumab and melphalan (FAM) during HSCT with a HLA matched sibling donor
Drug: Fludarabine
Fludarabine will be administered at 30 mg/m^2 IV daily for five days (Days -7 to -3).
Other Name: Fludara

Drug: Alemtuzumab
A test dose of alemtuzumab, 3 mg, will be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m^2 the second and 20 mg/m^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
Other Name: Campath

Drug: Melphalan
Melphalan will be administered at 140 mg/m^2 IV on Day -3 following fludarabine administration.
Other Name: Alkeran




Primary Outcome Measures :
  1. Immune Suppression-free, Rejection-free Survival [ Time Frame: Year 2 ]
    Immune suppression-free, rejection-free survival is defined as rejection-free survival off all systemic immunosuppressive agents. Participants who are off systemic immune suppression by 2-years post-transplant will be considered as being immune suppression free.


Secondary Outcome Measures :
  1. Regimen-Related Toxicity [ Time Frame: Day 42 ]
    Regimen-Related Toxicity (RRT) will be scored according to the Bearman scale. Major RRT, defined as grade 4 (causing death) in any organ system or grade 3 for pulmonary, cardiac, renal, oral mucosal, neurologic or hepatic, will be recorded. The assessment for RRT will be carried out on day 42 post-transplant.

  2. Number of Neurological Complications [ Time Frame: Up to Year 5 ]
    Neurological complications will be defined as any one of the following: seizures, intracranial hemorrhage, infarctive stroke (clinical or sub-clinical), and/or encephalopathy, including posterior reversible encephalopathy syndrome (PRES).

  3. Neutrophil Recovery [ Time Frame: Up to Year 5 ]
    Neutrophil recovery is defined as the first of 3 consecutive days following the nadir that the absolute neutrophil count is at least 500/µl.

  4. Platelet Recovery [ Time Frame: Up to Year 5 ]
    Platelet recovery is defined as the first day that the platelet count is at least 50,000/µl without a transfusion in the preceding 7 days.

  5. Graft Rejection [ Time Frame: Up to Year 5 ]
    This endpoint will be met when donor engraftment fails to occur as evidenced by lack of neutrophil recovery or donor chimerism (5% donor derived cells on chimerism testing; for sorted testing, at least 5% of both lineages must be donor derived). This endpoint will also be met when there is initial donor engraftment but donor chimerism is lost.

  6. Sustained Donor Engraftment [ Time Frame: Year 2 ]
    This endpoint will be met when the patient is off all immune suppression (or is still on immune suppression as treatment for GVHD) by one year, has normal marrow function, has no acute signs of SCD and has at least 5% donor derived cells on chimerism testing (for sorted testing at least 5% of both lineages must be donor derived). This endpoint will be assessed through 2 years.

  7. Cytomegalovirus (CMV) Viremia [ Time Frame: Day 180 ]
    CMV Viremia will be defined as the occurrence of a positive polymerase chain reaction (PCR) test prior to day 180.

  8. CMV Invasive Disease [ Time Frame: Up to Year 5 ]
    CMV invasive disease will be defined in accordance with the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures.

  9. Post-transplant Lymphoproliferative Disorder [ Time Frame: Up to Year 5 ]
    Post-transplant lymphoproliferative disorder will be defined in accordance with the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures.

  10. Other Infections [ Time Frame: Up to Year 5 ]
    Other Infections will be defined in accordance with the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures.

  11. Early Onset Acute GVHD [ Time Frame: Day 100 ]
    Early onset (before day 100) acute GVHD (including all grades, and stratified by grades) will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures using the NIH consensus criteria.

  12. Late Onset Acute GVHD [ Time Frame: Up to Year 5 ]
    Late onset (after day 100) acute GVHD will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures using the NIH consensus criteria.

  13. Chronic GVHD [ Time Frame: Up to Year 5 ]
    Chronic GVHD will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures using the NIH consensus criteria.

  14. Rejection-free Survival [ Time Frame: Up to Year 5 ]
    Rejection-free survival is defined as survival with sustained engraftment.

  15. Overall Survival [ Time Frame: Up to Year 5 ]
    Overall survival is defined as survival with or without rejection.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be at least 2 years and less than 10 years old and have a sickle hemoglobinopathy.
  • Patient must have an HLA identical sibling donor who is less than 10 years old. Sibling donors must not have any form of SCD. It is acceptable for the donor to carry a hemoglobinopathy trait.
  • Patients must meet criteria for symptomatic SCD as defined below.

    • Severe disease:

      • Previous clinical stroke, defined as a neurological deficit lasting longer than 24 hours plus new finding on head CT or brain MRI/MRA.
      • Progressive silent cerebral infarction, as evidenced by serial MRI scans that demonstrate the development of a succession of lesions (at least two temporally discreet lesions, each measuring at least 3 mm in greatest dimension on the most recent brain MRI/MRA) or the enlargement of a single lesion, initially measuring at least 3 mm). Lesions must be visible on T2-weighted MRI sequences.
      • Abnormal TCD testing (confirmed elevated velocities in any single vessel of TAMMV > 200 cm/sec for non-imaging TCD)
      • Significant vasculopathy on MRA (greater than 50% stenosis of > 2 arterial segments or complete occlusion of any single arterial segment).
      • Frequent (at least 3 per year for preceding 2 years) painful vaso-occlusive episodes (defined as episode lasting at least 4 hours and requiring hospitalization or outpatient treatment with parenteral opioids). If patient is on hydroxyurea and its use has been associated with a decrease in the frequency of episodes, the frequency should be gauged from the 2 years prior to the start of hydroxyurea.
      • Recurrent (at least 3 in lifetime) acute chest syndrome events which have necessitated erythrocyte transfusion therapy.
      • Any combination of at least 3 acute chest syndrome episodes and vaso-occlusive pain episodes (defined as above) yearly for 3 years. If patient is on hydroxyurea and its use has been associated with a decrease in the frequency of episodes, the frequency should be gauged from the 3 years prior to the start of hydroxyurea.
    • Less severe disease: to qualify as having less severe disease, patients must not meet criteria for severe disease and must have one of the following:

      • Asymptomatic cerebrovascular disease, as evidenced by one the following: Silent cerebral infarction with at least one lesion measuring at least 3 mm in one dimension that is visible on two planes on the most recent brain MRI, or, cerebral arteriopathy, as evidenced by conditional TCD (TAMMV>170cm/sec but <200cm/sec) on two separate scans >2 weeks apart). If patient has a conditional TCD, then a brain MRI/MRA to evaluate for vasculopathy is required.
      • 2 or more painful vaso-occlusive episodes (in lifetime) requiring hospitalization or outpatient treatment with parenteral opioids.
      • 2 or more episodes of acute chest syndrome (in lifetime) irrespective of SCD modifying therapy administered.
      • Any combination of at least 3 acute chest syndrome episodes and vaso-occlusive pain episodes (defined as above, lifetime).
  • Participant's parent or legal guardian must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
  • Patient must have been evaluated and parent(s)/legal guardian, and the patient as age appropriate as determined by the treating center, adequately counseled regarding treatment options for SCD by a pediatric hematologist.

Exclusion Criteria:

  • Bridging (portal to portal) fibrosis or cirrhosis of the liver.
  • Parenchymal lung disease stemming from SCD or other process defined as a diffusing capacity of the lungs for carbon monoxide (DLCO; corrected for hemoglobin) or forced vital capacity of less than 45% of predicted. Children unable to perform pulmonary function testing will be excluded if they require daytime oxygen supplementation.
  • Renal dysfunction with an estimated glomerular filtration rate (GFR) < 50% of predicted normal for age.
  • Cardiac dysfunction with shortening fraction < 25%.
  • Neurologic impairment other than hemiplegia, defined as full-scale intelligence quotient (IQ) of less than or equal to 70, quadriplegia or paraplegia, or inability to ambulate.
  • Lansky functional performance score < 70%.
  • Patient is HIV infected.
  • Donor is HIV infected.
  • Patient with unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate HSCT.
  • Patient's parent(s) or legal guardian is unable to understand the nature and the risks inherent in the HSCT process.
  • History of lack of adherence with medical care that would jeopardize transplant course.
  • Donor who for psychological, physiologic, or medical reasons is unable to tolerate a bone marrow harvest or receive general anesthesia.
  • Active viral, bacterial, fungal or protozoal infection.

    • Patients with viral upper respiratory tract infections should be asymptomatic for at least 7 days prior to enrollment. PCR testing for respiratory viruses (nasopharyngeal sample) should be negative at the start of the conditioning regimen. Exceptions may be made in patients with prolonged carriage (repeatedly positive over many weeks) of rhinovirus. These exceptions should be discussed with and approved by both study co-chairs and STAR Medical Director.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04018937


Contacts
Layout table for location contacts
Contact: Shelley Mays 404-785-9610 shelley.mays@choa.org
Contact: Ann Haight, MD ann.haight@choa.org

Locations
Layout table for location information
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Linda Eford    203-737-6219    linda.eford@yale.edu   
United States, District of Columbia
Children's National Health System Recruiting
Washington, District of Columbia, United States, 20010
Principal Investigator: Allistair Abraham, MD         
United States, Georgia
Children's Healthcare of Altanta Recruiting
Atlanta, Georgia, United States, 30322
Contact: Shelley Mays    404-785-9610    shelley.mays@choa.org   
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: Kimberly Kasow    919-966-1178    kkasow@med.unc.edu   
Principal Investigator: Kimberly Kasow, DO         
United States, New Jersey
Columbia University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Kimberly Kasow    919-966-1178    kkasow@med.unc.edu   
Principal Investigator: Kimberly Kasow, DO         
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Kimberly Kasow    919-966-1178    kkasow@med.unc.edu   
Principal Investigator: Kimberly Kasow, DO         
United States, North Carolina
University of North Carolina Medical Center Recruiting
Chapel Hill, North Carolina, United States, 27514
Contact: Kimberly Kasow    919-966-1178    kkasow@med.unc.edu   
Principal Investigator: Kimberly Kasow, DO         
United States, Ohio
University Hospitals Kent Health Center Recruiting
Kent, Ohio, United States, 44240
Contact: Kimberly Kasow    919-966-1178    kkasow@med.unc.edu   
Principal Investigator: Kimberly Kasow, DO         
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Kimberly Kasow, DO    919-966-1178    kkasow@med.unc.edu   
Principal Investigator: Kimberly Kasow, DO         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Principal Investigator: Jennifer Jaroscak, MD         
United States, Texas
Methodist Healthcare Systems Recruiting
San Antonio, Texas, United States, 78229
Contact: Kimberly Kasow    919-966-1178    kkasow@med.unc.edu   
Principal Investigator: Kimberly Kasow, DO         
Sponsors and Collaborators
Emory University
Investigators
Layout table for investigator information
Principal Investigator: Ann Haight, MD Emory University

Layout table for additonal information
Responsible Party: John Horan, Associate Professor, Emory University
ClinicalTrials.gov Identifier: NCT04018937    
Other Study ID Numbers: IRB00093513
First Posted: July 15, 2019    Key Record Dates
Last Update Posted: July 15, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by John Horan, Emory University:
Pediatrics
Hematopoietic stem cell transplantation
HLA matched sibling
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Fludarabine
Fludarabine phosphate
Melphalan
Alemtuzumab
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological